Literature DB >> 18068983

Acylguanidine inhibitors of beta-secretase: optimization of the pyrrole ring substituents extending into the S1' substrate binding pocket.

Lee D Jennings1, Derek C Cole, Joseph R Stock, Mohani N Sukhdeo, John W Ellingboe, Rebecca Cowling, Guixian Jin, Eric S Manas, Kristi Y Fan, Michael S Malamas, Boyd L Harrison, Steve Jacobsen, Rajiv Chopra, Peter A Lohse, William J Moore, Mary-Margaret O'Donnell, Yun Hu, Albert J Robichaud, M James Turner, Erik Wagner, Jonathan Bard.   

Abstract

The proteolytic enzyme beta-secretase (BACE-1) produces amyloid beta (Abeta) peptide, the primary constituent of neurofibrillary plaques, implicated in Alzheimer's disease, by cleavage of the amyloid precursor protein. A small molecule inhibitor of BACE-1, (diaminomethylene)-2,5-diphenyl-1H-pyrrole-1-acetamide (1, BACE-1 IC(50)=3.7 microM), was recently described, representing a new small molecule lead. Initial SAR investigation demonstrated the potential of accessing the nearby S(3) and S(1)(') substrate binding pockets of the BACE-1 enzyme by building substituents off one of the phenyl substituents and guanidinyl functional group. We report here the optimization of guanidinyl functional group substituents on 1, leading to potent submicromolar BACE-1 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18068983     DOI: 10.1016/j.bmcl.2007.11.043

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  8 in total

Review 1.  The β-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-β reduction to downstream disease-relevant effects.

Authors:  Ulf Neumann; Rainer Machauer; Derya R Shimshek
Journal:  Br J Pharmacol       Date:  2019-03-10       Impact factor: 8.739

Review 2.  beta-Secretase as a therapeutic target for Alzheimer's disease.

Authors:  Arun K Ghosh; Sandra Gemma; Jordan Tang
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

Review 3.  Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease.

Authors:  Akanksha Kulshreshtha; Poonam Piplani
Journal:  Neurol Sci       Date:  2016-06-01       Impact factor: 3.307

Review 4.  The structural evolution of β-secretase inhibitors: a focus on the development of small-molecule inhibitors.

Authors:  Stefania Butini; Simone Brogi; Ettore Novellino; Giuseppe Campiani; Arun K Ghosh; Margherita Brindisi; Sandra Gemma
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

5.  Comparative molecular field analysis and comparative molecular similarity indices analysis of hydroxyethylamine derivatives as selective human BACE-1 inhibitor.

Authors:  Ashish Pandey; Jignesh Mungalpara; C Gopi Mohan
Journal:  Mol Divers       Date:  2009-03-28       Impact factor: 2.943

Review 6.  BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease.

Authors:  Arun K Ghosh; Heather L Osswald
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

7.  Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?

Authors:  Alfredo Robles
Journal:  Open Neurol J       Date:  2009-04-02

Review 8.  New directions for protease inhibitors directed drug discovery.

Authors:  Yoshio Hamada; Yoshiaki Kiso
Journal:  Biopolymers       Date:  2016-11-04       Impact factor: 2.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.